DJIA 16,380.41 263.17 1.63%
NASDAQ 4,258.44 41.05 0.97%
S&P 500 1,886.76 24.00 1.29%
market minute promo

369.64 28.93 (8.49%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

REGN $369.64 8.49%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $366.99
Previous Close $340.71
Daily Range $362.02 - $376.88
52-Week Range $257.69 - $376.88
Market Cap $37.4B
P/E Ratio 96.79
Dividend (Yield) $0.00 (0.0%)
Volume 2,470,720
Average Daily Volume 782,927
Current FY EPS $7.95

Sector

Healthcare

Industry

Drugs

Regeneron Pharmaceuticals, Inc. (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary Rss Feed

3 Small-Cap Biotech Stocks to Buy if the Market Crashes

Falling markets may be creating an opportunity to pick up these three biotechnology companies at discount prices.

Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14)

InsiderInsights.com Daily Round Up 10/17/14: REGN, KEY, ALSN, AGCO

'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors

Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy - Analyst Blog

Friday's ETF Movers: BBH, GDX

S&P 500 Analyst Moves: REGN

Cramer: Regeneron's Head-to-Head Results 'Very Positive'

3 Stocks Reiterated As A Buy: UNH, BIDU, REGN

Benzinga's Volume Movers

EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both Bevacizumab And

EYLEA Injection Demonstrates Significantly Greater Gains In Visual Acuity than Both Bevacizumab And Ranibizumab In NIH-Sponsored Diabetic Macular Edema Study

See More REGN News...

REGN's Top Competitors

REGN $369.64 (8.49%)
Current stock: REGN
AMGN $133.69 (2.48%)
Current stock: AMGN
GILD $100.75 (3.99%)
Current stock: GILD
BIIB $306.71 (1.31%)
Current stock: BIIB